• Home
  • Search Results
  • Drug target validation in primary human natural killer cells using CRISPR RNP.

Drug target validation in primary human natural killer cells using CRISPR RNP.

Journal of leukocyte biology (2021-01-20)
Jai Rautela, Elliot Surgenor, Nicholas D Huntington
ABSTRACT

The ability to genetically modify CD8 T cells using viral gene delivery has facilitated the development of next generation of cancer immunotherapies such as chimeric Ag receptor (CAR) T cells engineered to specifically kill tumor cells. Development of immunotherapies targeting NK cells have stalled in part by their resistance to traditional viral gene delivery systems. Here, an efficient approach is described to genetically edit human NK cells by electroporation and CRISPR-Cas9 ribonucleoprotein (RNP) complexes. Electroporation pulse codes and buffer optimization for protein uptake by human NK cells and viability, and the efficiency of this approach over other methods are detailed. To highlight the transformative step this technique will have for NK cell immunotherapy drug discovery, NCR1 and CISH are deleted in primary human NK cells and murine findings are validated on their key roles in regulating NK cell antitumor function.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Human Serum, (from male AB clotted whole blood), USA origin, sterile-filtered
Sigma-Aldrich
Fluorescein isothiocyanate–dextran, average mol wt 70,000, (FITC:Glucose = 1:250)
Sigma-Aldrich
Anti-phospho-STAT5A/B (Tyr694/699) Antibody, clone 8-5-2, clone 8-5-2, Upstate®, from mouse